Pharmacologic and biologic therapies in cancer care.
Although Coley first began treating patients more than 100 years ago, he was far ahead of his time in observing the link between boosting the immune system and improving response and survival. The field of immunotherapy has advanced rapidly, and patients' requests to be treated with the newer biologic agents far outweigh requests to be treated with earlier agents such as Coley Toxins (Coley Toxins, 2000).
Decker
G M
GM
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000627:therapeutic use; D044482:Benzeneacetamides; D000529:Complementary Therapies; D004338:Drug Combinations; D005973:Glutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010648:Phenylacetates / Q000627:therapeutic use; D010881:Piperidones / Q000627:therapeutic use; D012106:Research
D000970:Antineoplastic Agents; D001427:Bacterial Toxins; D044482:Benzeneacetamides; D004338:Drug Combinations; D010648:Phenylacetates; D010881:Piperidones; D005973:Glutamine; C092038:antineoplaston AS 2-1; C052091:antineoplaston A10